...
首页> 外文期刊>Drug and Chemical Toxicology >Evaluation of the effects of risedronate on hepatic microsomal drug metabolizing enzyme activities following administration to rats for 14 days: lack of an induction response.
【24h】

Evaluation of the effects of risedronate on hepatic microsomal drug metabolizing enzyme activities following administration to rats for 14 days: lack of an induction response.

机译:对大鼠给药14天后,利塞膦酸盐对肝微粒体药物代谢酶活性的影响评估:缺乏诱导反应。

获取原文
获取原文并翻译 | 示例
           

摘要

Risedronate ([1-hydroxy-2-(3-pyridinyl)-ethylidene[bis]phosphonic acid] monosodium salt) was evaluated for induction of hepatic microsomal drug metabolizing enzymes in male and female Sprague Dawley rats (N = 4/sex/dose group). Main study animals received water (vehicle control), risedronate (0.1, 0.8, 4, or 16 mg/kg/day) or phenobarbital (80 mg/kg/day, positive control) by daily oral gavage for 14 consecutive days. Recovery study animals received water, risedronate (16 mg/kg/day) or phenobarbital (80 mg/kg/day) by daily oral gavage for 14 consecutive days and then were maintained drug-free for 14 days to evaluate the reversibility of any observed effects. At the conclusion of each study the animals were sacrificed, the liver removed, weighed and the microsomal subcellular fraction prepared. The hepatic microsomal fraction was then evaluated for protein content, cytochrome P450, and the activities of aniline hydroxylase, aminopyrine N-demethylase, ethoxycoumarin O-deethylase and p-nitrophenol UDP-glucuronosyltransferase. Risedronate was well tolerated during the dosing phase of the study as evidenced by clinical observations, body weight gain and food consumption which were not significantly different from the vehicle controls. Risedronate did not significantly increase (P > 0.05) liver weight, liver/body weight ratio, protein content, P450, aniline hydroxylase, aminopyrine N-demethylase, ethoxycoumarin O-deethylase or p-nitrophenol UDP-glucuronosyltransferase in rats of either sex when compared to vehicle controls. As expected, the hepatic microsomal enzyme inducer phenobarbital significantly increased (P < 0.05) liver weight, liver/body weight ratio, protein content (males only), P450, aniline hydroxylase (males only), aminopyrine N-demethylase (males only), ethoxycoumarin O-deethylase and p-nitrophenol UDP-glucuronosyltransferase in rats relative to vehicle controls. Following the 14 day drug-free recovery period the induction parameters increased by phenobarbital reversed to vehicle control levels. The results obtained in this well controlled study indicate that risedronate is not an inducer of hepatic microsomal drug metabolizing enzymes in the rat.
机译:评价了利塞膦酸([1-羟基-2-(3-吡啶基)-亚乙基[双]膦酸]一钠盐)对雄性和雌性Sprague Dawley大鼠肝微粒体药物代谢酶的诱导(N = 4 /性别/剂量)组)。主要研究动物连续连续14天每天口服管饲水(媒介物对照),利塞膦酸盐(0.1、0.8、4或16 mg / kg /天)或苯巴比妥(80 mg / kg /天,阳性对照)。恢复研究动物连续连续14天每天口服灌胃水,利塞膦酸盐(16 mg / kg /天)或苯巴比妥(80 mg / kg /天),然后保持无药14天,以评估观察到的任何动物的可逆性效果。在每个研究结束时,处死动物,取出肝脏,称重,并制备微粒体亚细胞级分。然后评估肝微粒体级分的蛋白质含量,细胞色素P450以及苯胺羟化酶,氨基比林N-脱甲基酶,乙氧基香豆素O-脱乙基酶和对硝基苯酚UDP-葡萄糖醛酸转移酶的活性。临床研究,体重增加和食物摄入与车辆对照相比无显着差异,在研究的给药阶段中,利塞膦酸耐受性良好。比较时,利塞膦酸并未显着增加(P> 0.05)肝脏重量,肝脏/体重比,蛋白质含量,P450,苯胺羟化酶,氨基比林N-脱甲基酶,乙氧基香豆素O-脱乙基酶或对硝基苯酚UDP-葡萄糖醛酸转移酶车辆控制。如预期的那样,肝微粒体酶诱导剂苯巴比妥显着增加(P <0.05)肝脏重量,肝脏/体重比,蛋白质含量(仅男性),P450,苯胺羟化酶(仅男性),氨基比林N-脱甲基酶(仅男性),相对于媒介物对照,大鼠中的乙氧基香豆素O-脱乙基酶和对硝基苯酚UDP-葡糖醛酸糖基转移酶。在14天无药恢复期后,苯巴比妥将诱导参数增加至媒介物对照水平。在这项受到良好控制的研究中获得的结果表明,利塞膦酸盐不是大鼠肝微粒体药物代谢酶的诱导剂。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号